Innate Pharma S.A. IPHA
Set alert
1.40 USD -0.06 -4.11%
At close · Nov 2
1.39 -0.01 -0.71%
After hours · Nov 2, 4:00 PM ET
1.38 Day range 1.44
1.17 52-week range 2.71
- YTD
- -20.00%
- 1 year
- -28.93%
- Open
- 1.44
- Prev close
- 1.46
- Mkt cap
- 156.38M
- Vol
- 32.77K
- Avg vol
- 159.36K
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.38
- High
- 1.44
- Forward P/E
- 4.67
- Beta
- 0.87
- Short ratio
- 5.63
- Inst. own
- 0.50%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Mar 21, 2024
- 50-d avg
- 1.82
- 200-d avg
- 2.23
- 1y target
- 7.41
5Y chart
Events in this range
- Mar 24, 2022Earnings: —; estimate 0; surprise —%
- Mar 23, 2023Earnings: —; estimate 0; surprise —%
- Mar 21, 2024Earnings: —; estimate 0; surprise —%
- May 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Jun 12, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Sep 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 12, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 15, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Dec 9, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (108)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 21, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 7, 2026 | 1 month ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| SMA: Bullish | May 11, 2026 | 5 months ago |
| MACD: Buy Signal | May 11, 2026 | 5 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| RSI: Oversold | Mar 16, 2026 | 7 months ago |
| SMA: Bearish | Feb 2, 2026 | 9 months ago |
| SMA: Bullish | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Nov 3, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 13, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 15, 2025 | 1 year ago |
Newest 20 of 108.
Financial health
Altman Z-Score
-22.77 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -2.8×
FY 2016 5y median -4.8× FY 2025
P/S 47.8×
FY 2016 5y median 11.4× FY 2025
P/B -6.1×
FY 2016 5y median 4.1× FY 2025
P/FCF -3.8×
FY 2016 5y median -6.1× FY 2025
EV/EBITDA -2.9×
FY 2016 5y median -6.0× FY 2025
EV/Sales 45.8×
FY 2016 5y median 8.6× FY 2025
FCF Yield -26.2%
FY 2016 5y median -16.4% FY 2025
Profitability
Gross Margin 100.0%
FY 2016 5y median 10.8% FY 2025
Operating Margin -1916.9%
FY 2016 5y median -394.9% FY 2025
Net Margin -1764.5%
FY 2016 5y median -392.0% FY 2025
ROE 226.7%
FY 2016 5y median -49.2% FY 2025
ROIC -153.3%
FY 2016 5y median -34.1% FY 2025
ROA -78.4%
FY 2016 5y median -28.0% FY 2025
Growth (YoY)
Revenue -77.9%
FY 2016 FY 2025
Operating Income -3.6%
FY 2016 FY 2025
EPS (diluted) 13.1%
FY 2016 FY 2025
Free Cash Flow -379.1%
FY 2016 FY 2025
Financial Health
Current Ratio 1.3×
FY 2016 5y median 2.6× FY 2025
Quick Ratio 1.3×
FY 2016 5y median 2.6× FY 2025
Debt / Equity -1.0×
FY 2016 5y median 0.8× FY 2025
Net Debt / EBITDA 0.1×
FY 2016 5y median 1.4× FY 2025
Interest Coverage -121×
FY 2016 5y median -121× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
